State Street Corp increased its position in shares of BioTime, Inc. (NYSEAMERICAN:BTX) by 10.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,345,379 shares of the biotechnology company’s stock after purchasing an additional 125,833 shares during the period. State Street Corp owned 1.21% of BioTime worth $4,238,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in BioTime by 15.1% during the first quarter. Vanguard Group Inc. now owns 3,146,178 shares of the biotechnology company’s stock worth $10,855,000 after purchasing an additional 413,073 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of BioTime by 51.7% during the second quarter. Schwab Charles Investment Management Inc. now owns 163,100 shares of the biotechnology company’s stock valued at $514,000 after acquiring an additional 55,600 shares during the last quarter. Dimensional Fund Advisors LP acquired a new stake in shares of BioTime during the second quarter valued at about $380,000. Metropolitan Life Insurance Co. NY increased its position in shares of BioTime by 14.7% during the first quarter. Metropolitan Life Insurance Co. NY now owns 57,694 shares of the biotechnology company’s stock valued at $199,000 after acquiring an additional 7,411 shares during the last quarter. Finally, Russell Investments Group Ltd. increased its position in shares of BioTime by 11.6% during the second quarter. Russell Investments Group Ltd. now owns 107,460 shares of the biotechnology company’s stock valued at $339,000 after acquiring an additional 11,157 shares during the last quarter.

BioTime, Inc. (NYSEAMERICAN BTX) traded down $0.03 during midday trading on Friday, hitting $2.43. 390,200 shares of the stock traded hands, compared to its average volume of 352,883. BioTime, Inc. has a twelve month low of $2.19 and a twelve month high of $3.97.

In other BioTime news, Director Broadwood Partners, L.P. acquired 2,692,307 shares of the stock in a transaction dated Friday, October 13th. The stock was acquired at an average price of $2.60 per share, with a total value of $6,999,998.20. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

BTX has been the subject of a number of recent analyst reports. Zacks Investment Research upgraded shares of BioTime from a “hold” rating to a “buy” rating and set a $2.75 price target for the company in a research report on Wednesday, November 15th. BidaskClub upgraded shares of BioTime from a “sell” rating to a “hold” rating in a research report on Thursday, September 28th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. BioTime has a consensus rating of “Hold” and an average price target of $5.08.

TRADEMARK VIOLATION WARNING: “BioTime, Inc. (BTX) Position Raised by State Street Corp” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.watchlistnews.com/biotime-inc-btx-position-raised-by-state-street-corp/1752032.html.

BioTime Company Profile

BioTime, Inc is a clinical-stage biotechnology company focused on developing and commercializing products addressing degenerative diseases. Its clinical programs are based on two platform technologies: pluripotent stem cells and cell/drug delivery platform technologies. The foundation of its cell delivery platform is its HyStem cell and drug delivery matrix technology.

Want to see what other hedge funds are holding BTX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioTime, Inc. (NYSEAMERICAN:BTX).

Institutional Ownership by Quarter for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.